Glenmark Pharmaceuticals receives tentative ANDA approval for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%|0.064%
Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval by the United States Food & Drug Administration (U.S. FDA) for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%|0.064%, the generic version of Enstilar®1 Foam, 0.005%|0.064%, of Leo Pharma AS. According to IQVIA™sales data for the 12 month period ending March 2022, the Enstilar® Foam, 0.005%|0.064% market2 achieved […]









